Fazia A Mir1, Sunanda V Kane2. 1. Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA. 2. Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN, USA. Kane.sunanda@mayo.edu.
Abstract
PURPOSE OF REVIEW: Patients with inflammatory bowel disease (IBD) are not receiving preventative care services at the same rate as the general population. IBD patients are at increased risk for infections, osteoporosis, and certain malignancies secondary to their disease and as they are on immunosuppressive therapy. They are a younger population and often times consider their gastroenterologist as their primary care physician. In this review, we discuss up-to-date evidence pertaining to vaccine-preventable illnesses in the immunosuppressed IBD patient, screening for bone health, cervical cancer, skin malignancies, psychological wellbeing, and smoking cessation. RECENT FINDINGS: Vaccinations are recommended in the IBD population as they are immunosuppressed and at increased risk for acquiring influenza and pneumonia. Not only are they at greater risk to acquire it but they also have a much severe complicated course. Ideally, IBD patients should be vaccinated prior to initiating immunosuppression and most inactive vaccines can be administered to them while they are on therapy. All IBD patients should be encouraged to stop smoking and have adequate vitamin D intake along with appropriate applicable cancer screenings. Gastroenterologists must work in collaboration with primary care providers along with other specialists to help provide our patients well-rounded care for their IBD.
PURPOSE OF REVIEW: Patients with inflammatory bowel disease (IBD) are not receiving preventative care services at the same rate as the general population. IBD patients are at increased risk for infections, osteoporosis, and certain malignancies secondary to their disease and as they are on immunosuppressive therapy. They are a younger population and often times consider their gastroenterologist as their primary care physician. In this review, we discuss up-to-date evidence pertaining to vaccine-preventable illnesses in the immunosuppressed IBD patient, screening for bone health, cervical cancer, skin malignancies, psychological wellbeing, and smoking cessation. RECENT FINDINGS: Vaccinations are recommended in the IBD population as they are immunosuppressed and at increased risk for acquiring influenza and pneumonia. Not only are they at greater risk to acquire it but they also have a much severe complicated course. Ideally, IBD patients should be vaccinated prior to initiating immunosuppression and most inactive vaccines can be administered to them while they are on therapy. All IBD patients should be encouraged to stop smoking and have adequate vitamin D intake along with appropriate applicable cancer screenings. Gastroenterologists must work in collaboration with primary care providers along with other specialists to help provide our patients well-rounded care for their IBD.
Entities:
Keywords:
Bone health; Health maintenance in inflammatory bowel disease; Preventative care; Skin cancer; Vaccinations
Authors: Jean-François Rahier; Pavol Papay; Julia Salleron; Shaji Sebastian; Manuela Marzo; Laurent Peyrin-Biroulet; Valle Garcia-Sanchez; Walter Fries; Dirk P van Asseldonk; Klaudia Farkas; Nanne K de Boer; Taina Sipponen; Pierre Ellul; Edouard Louis; Simon T C Peake; Uri Kopylov; Jochen Maul; Badira Makhoul; Gionata Fiorino; Yazdan Yazdanpanah; Maria Chaparro Journal: Gut Date: 2011-01-26 Impact factor: 23.059
Authors: Gurtej Malhi; Amir Rumman; Reka Thanabalan; Kenneth Croitoru; Mark S Silverberg; A Hillary Steinhart; Geoffrey C Nguyen Journal: J Crohns Colitis Date: 2015-04-23 Impact factor: 9.071
Authors: Tiago Nunes; Maria Josefina Etchevers; Olga Merino; Sonia Gallego; Valle García-Sánchez; Ignacio Marín-Jiménez; Luis Menchén; Manuel Barreiro-de Acosta; Guillermo Bastida; Sara García; Elena Gento; Daniel Ginard; Fernando Gomollón; Maite Arroyo; David Monfort; Esther García-Planella; Benito Gonzalez; Carme Loras; Carles Agustí; Carolina Figueroa; Miquel Sans Journal: Inflamm Bowel Dis Date: 2013-01 Impact factor: 5.325